TY - JOUR
AU - Koo, John
AB - Studies investigating the molecular basis of psoriasis have established the central roles of TNFa, interleukin (IL)-12, IL-22 and IL-23, and now there is increasing evidence that IL-17 plays a vital role in the complex pathophysiology of this disease. Preclinical and phase II studies of medications targeting IL-17 and its receptor have thus far proved to be promising.
TI - Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
JF - Journal of drugs in dermatology : JDD
DA - 2016-12-13
UR - https://www.deepdyve.com/lp/pubmed/anti-il-17-agents-for-psoriasis-a-review-of-phase-iii-data-SXIr5Z63iK
SP - 311
EP - 6
VL - 15
IS - 3
DP - DeepDyve
ER -